Orchestra BioMed Shares Rise On FDA Approval Of IDE For BACKBEAT Study
Shares of Orchestra BioMed Holdings, Inc. (OBIO) are rising over 17% on Tuesday after FDA approved an investigational device exemption (IDE) to initiate the global pivotal BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) study.
Source: rttnews.com